Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Hepatitis C Virus
Research reports from Z.Y. Keck and co-authors provide new insights into hepatitis C virus
September 10th, 2008
According to recent research from the United States, "Development of a successful hepatitis C virus (HCV) vaccine requires the definition of neutralization epitopes that are conserved among different HCV genotypes." "Five human monoclonal antibodies (HMAbs) are described that cross-compete with other antibodies to a cluster of overlapping epitopes, previously designated domain B. Each HMAb broadly neutralizes retroviral pseudotype particles expressing HCV E1 and E2 glycoproteins, as well as the infectious chimeric genotype la and genotype 2a viruses," wrote Z.Y. Keck and colleagues. The researchers concluded: "Alanine substitutions of residues within...
Source: Vaccine Weekly (2008-09-10)
|
